Physician profile
Harold E Quan
NPI 1033220256
$3,578.00
in general payments reported to CMS, 2019-2025
23 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $240 · 2021: $934 · 2022: $719 · 2023: $89.73 · 2024: $640 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,149.72 | 2020-2025 | Airsupra, Andexxa, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.51 | 2020-2022 | |
| Glaxosmithkline, LLC. | $382.16 | 2019-2025 | Arexvy, Shingrix |
| Pfizer INC. | $170.18 | 2019-2020 | |
| Harmony Biosciences LLC | $169.87 | 2025 | |
| Janssen Pharmaceuticals, INC | $148.05 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $138.88 | 2021 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2024 | Nuzyra |
| Alnylam Pharmaceuticals INC. | $124.99 | 2024 | Amvuttra |
| Amarin Pharma, INC. | $105.93 | 2020-2021 | |
| Esperion Therapeutics, INC. | $100.19 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $90.90 | 2019 | |
| Abiomed | $82.79 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $64.02 | 2019-2023 | Camzyos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.95 | 2024-2025 | |
| Biotronik INC. | $40.00 | 2019 | |
| Amgen INC. | $25.39 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $24.93 | 2023 | Arcalyst |
| Sanofi Pasteur INC. | $24.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.50 | 2019 | |
| Akcea Therapeutics, INC. | $17.62 | 2019 | |
| Vertiflex, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Quan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.